Sermonix Receives FDA Fast Track Designation for Investigational Drug Lasofoxifene
28 mai 2019 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, May 28, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development of female-specific oncology products, today...
Sermonix to Present Poster on ‘Lasofoxifene as a Potential Treatment for ER+ Metastatic Breast Cancer’ at 2019 ASCO Annual Meeting
07 mai 2019 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, May 07, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology...
Sermonix Pharmaceuticals Adds Three New Members to Its Board of Directors
23 avr. 2019 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, April 23, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific...
Sermonix to Present at Boston Oncology Investor Conference on Potential for Lasofoxifene in Metastatic Breast Cancer Treatment
11 mars 2019 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, March 11, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific...
Sermonix to Present Poster at ENDO 2019 on Lasofoxifene’s ‘Potent Anti-Tumor Activity’ in ESR1 Hormone-Resistant Breast Cancer
04 mars 2019 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, March 04, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific...
Sermonix Pharmaceuticals to Present Three Posters Focused on Precision Medicine in the Treatment of Metastatic Breast Cancer at San Antonio Breast Cancer Symposium
14 nov. 2018 10h00 HE
|
Sermonix Pharmaceuticals LLC
Posters to be displayed at Dec. 4-8 conference address introduction of Phase 2 study of investigational drug lasofoxifene, its effect on breast cancer and lung and liver metastasis in an in vivo...
Sermonix Launches Phase 2 Trial to Evaluate Investigational Oral Lasofoxifene as a Targeted Precision Treatment for Women With ESR1 Mutations in Metastatic Breast Cancer
09 oct. 2018 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific...
David Thompson, PhD to Lead Azure Biotech as President
08 mars 2016 10h32 HE
|
Azure Biotech, Inc.
GALES FERRY, CT--(Marketwired - March 08, 2016) - Azure Biotech, Inc. a private biotechnology company developing novel formulations of lasofoxifene announced today that David Thompson, PhD will...
Azure Biotech Announces Hiring of Ralph Makar as CEO
17 déc. 2013 08h00 HE
|
Azure Biotech, Inc
NEW YORK, NY--(Marketwired - December 17, 2013) -
Azure Biotech Inc. today announced that it has hired Ralph Makar as Chief Executive Officer (CEO), effective...